11.06.2013 - Bill Gates and EU Research Commissioner Máire Geoghegan-Quinn have signed a partnership to fight neglected diseases.
The multibillion partnership of the Bill & Melinda Gates Foundation and the European Commission aims at fighting and other poverty-related diseases such as HIV/AIDS, tuberculosis malaria, lymphatic filariasis or sleeping sickness, which affect more than one billion people globally. "The foundation is completely committed to supporting efforts to develop life-saving products to help solve some of the world’s toughest problems“, said Gates. The partnership will develop at least one improved product per year, according to Geoghegan-Quinn.
Much of the work will be carried out through the European and Developing Countries Clinical Trials Partnership (EDCTP), which so far involves 16 European and 30 sub-Saharan African countries. The European Commission has proposed funding of up to €1 bn from the EU budget to match the contributions of the European partner countries.
Between 2007 and 2011, Gates and the EU invested around €2.4bn in R&D on neglected infectious diseases. Under the agreement, the partners will develop new drugs, vaccines and diagnostics suited to the needs of the population of poor countries , improve health systems and ensure the delivery of such products. Furthermore, the Gates Foundation and the Commission will launch a joint innovation prize in 2014 in order to honour current approaches to global health.
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.